Alto Neuroscience Inc. (ANRO) Stock
Fundamentals
Source: third-party data provider, as of October 15, 2026
Compare with ANRO
Recent news

Alto Neuroscience Announces Participation in Upcoming Investor Conferences
Alto Neuroscience Announces Participation in Upcoming Investor Conferences
ANRO

Alto Neuroscience Promotes Nick Smith to President and Chief Financial Officer
Alto Neuroscience Promotes Nick Smith to President and Chief Financial Officer
ANRO

Alto Neuroscience Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Alto Neuroscience Reports Second Quarter 2026 Financial Results and Recent Business Highlights
ANRO

Alto Neuroscience Announces Pricing of $100.0 Million Underwritten Registered Direct Offering of Common Stock
Alto Neuroscience Announces Pricing of $100.0 Million Underwritten Registered Direct Offering of Common Stock
ANRO
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 21.59
- MACD 12/26/9
- -2.28
- EMA 9 of MACD
- -2.04
- MACD histogram
- -0.25
- SMA 50
- $30.25
- Price below SMA 50
- EMA 50
- $27.91
- Price below EMA 50
- SMA 200
- $23.89
- Price below SMA 200
- EMA 200
- $23.70
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of October 14, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 3 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
No data available
Debt & Balance Sheet
No data available
Revenue to Profit
No data available
Earnings
No data available
Source: third-party data provider
Latest news

Alto Neuroscience Announces Participation in Upcoming Investor Conferences
Alto Neuroscience Announces Participation in Upcoming Investor Conferences
ANRO

Alto Neuroscience Promotes Nick Smith to President and Chief Financial Officer
Alto Neuroscience Promotes Nick Smith to President and Chief Financial Officer
ANRO

Alto Neuroscience Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Alto Neuroscience Reports Second Quarter 2026 Financial Results and Recent Business Highlights
ANRO

Alto Neuroscience Announces Pricing of $100.0 Million Underwritten Registered Direct Offering of Common Stock
Alto Neuroscience Announces Pricing of $100.0 Million Underwritten Registered Direct Offering of Common Stock
ANRO

Alto Neuroscience Highlights Nature Medicine Publication Demonstrating Significant Effects of Pramipexole on Anhedonia
Alto Neuroscience Highlights Nature Medicine Publication Demonstrating Significant Effects of Pramipexole on Anhedonia
ANRO

ANRO Stock Drops 7% After Disappointing Schizophrenia Study Results – But Analyst Sees Dip As Attractive Entry Point
ANRO Stock Drops 7% After Disappointing Schizophrenia Study Results – But Analyst Sees Dip As Attractive Entry Point
ANRO

ANRO Stock Falls After Hours On Failed Schizophrenia Study Results
ANRO Stock Falls After Hours On Failed Schizophrenia Study Results
ANRO

Are These 4 Biotech Stocks Set to Beat Q3 Earnings Estimates?
Are These 4 Biotech Stocks Set to Beat Q3 Earnings Estimates?
ANRO

5 Stocks Under $10 Growing 50% Or More
5 Stocks Under $10 Growing 50% Or More
ANRO
News tone: automated (AI) classification of the article's content, not a price prediction.
About Alto Neuroscience Inc.
Alto Neuroscience Inc is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individual's neurobiology to develop personalized and effective treatment options. The company currently consists of different clinical-stage assets such as ALTO-100, ALTO-202, ALTO-207, ALTO-101, and ALTO-300 among others initially targeting depressive disorders and schizophrenia populations as identified by independent brain-based biomarkers.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Amit Etkin M.D., Ph.D. | Founder, CEO & Chairman of the Board | 1977 |
| Mr. Nicholas C. Smith | CFO & President | 1989 |
| Mr. Michael C. Hanley M.B.A. | Chief Operating Officer | 1974 |
| Mr. Dan Segal B.Sc. (Hons), BCom, CA, MSc | Co-Founder & Strategic Advisor | 1962 |
| Ms. Erin R. McQuade J.D. | General Counsel, Chief Administrative Officer & Corporate Secretary | 1975 |
| Mr. Adam Savitz M.D., Ph.D. | Chief Medical Officer | 1966 |
| Ms. Jessica Powell | Chief Development Officer | 1975 |
Fundamentals
Valuation
Earnings Per Share
Income Statement
Dividend
Source: third-party data provider, as of October 15, 2026
Technical indicators
- RSI 14
- 21.59
- MACD 12/26/9
- -2.28
- EMA 9 of MACD
- -2.04
- MACD histogram
- -0.25
- SMA 50
- $30.25
- Price below SMA 50
- EMA 50
- $27.91
- Price below EMA 50
- SMA 200
- $23.89
- Price below SMA 200
- EMA 200
- $23.70
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of October 14, 2026. Technical data, not a recommendation.
Analyst views
3 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $26.00
- Average
- $39.33
- High
- $55.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +8.0 | +8.5 | +29.7 | -27.5 | -14.2 |



